NZ778293A - Anti-clec2d antibodies and methods of use thereof - Google Patents

Anti-clec2d antibodies and methods of use thereof

Info

Publication number
NZ778293A
NZ778293A NZ778293A NZ77829320A NZ778293A NZ 778293 A NZ778293 A NZ 778293A NZ 778293 A NZ778293 A NZ 778293A NZ 77829320 A NZ77829320 A NZ 77829320A NZ 778293 A NZ778293 A NZ 778293A
Authority
NZ
New Zealand
Prior art keywords
clec2d
antibodies
methods
llt1
prognostic
Prior art date
Application number
NZ778293A
Other languages
English (en)
Inventor
Kavitha Iyer Rodrigues
Maloy Ghosh
Sunit Maity
Yogendra Manjunath Bangalore Muniraju
Sathyabalan Murugesan
Sanghamitra Bhattacharjee
Vivek Halan
Subhra Prakash Chakrabarty
Ashvini Kumar Dubey
Anurag Tiwari
Kirthana Mysore Vasudevarao Sindhe
Pallavi Lahiri
Sahana Bhima Rao
Prachi *
Shruti Srivastava
Rao Shreesha Ramesh
Bharath Ravindra Shenoy
Nikitha Markanda
Bhagyashree Dikey
Bairavabalakumar Natarajan
Original Assignee
Zumutor Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zumutor Biologics Inc filed Critical Zumutor Biologics Inc
Publication of NZ778293A publication Critical patent/NZ778293A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ778293A 2019-02-11 2020-02-10 Anti-clec2d antibodies and methods of use thereof NZ778293A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941005395 2019-02-11
PCT/US2020/017518 WO2020167668A1 (en) 2019-02-11 2020-02-10 Anti-clec2d antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
NZ778293A true NZ778293A (en) 2026-02-27

Family

ID=69811875

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ778293A NZ778293A (en) 2019-02-11 2020-02-10 Anti-clec2d antibodies and methods of use thereof

Country Status (10)

Country Link
US (2) US11827710B2 (https=)
EP (1) EP3924385A1 (https=)
JP (2) JP7612591B2 (https=)
KR (1) KR20220007584A (https=)
AU (1) AU2020222891A1 (https=)
CA (1) CA3129818A1 (https=)
IL (1) IL285401A (https=)
NZ (1) NZ778293A (https=)
SG (1) SG11202108403UA (https=)
WO (1) WO2020167668A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220007584A (ko) 2019-02-11 2022-01-18 주무토르 바이오로직스 인코포레이티드 항-clec2d 항체 및 이의 사용 방법
CN115443140A (zh) * 2020-04-02 2022-12-06 苏州恒康生命科学有限公司 人ror-1抗体和抗ror-1-car-t细胞
CN116547003A (zh) * 2020-10-05 2023-08-04 莫纳什大学 Clec9a抗体
WO2022202985A1 (ja) * 2021-03-24 2022-09-29 森永乳業株式会社 ペプチド、及び該ペプチドを有効成分として含有する組成物
WO2023039242A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use
CN114685663B (zh) * 2022-04-07 2023-09-08 西南大学 一种抗胆固醇依赖性细胞溶素的抗体及其应用
PE20251175A1 (es) * 2022-05-31 2025-04-23 Pfizer Anticuerpos anti-bmp9 y metodos de uso de los mismos
CN120129704A (zh) * 2022-11-01 2025-06-10 俄勒冈州健康与服务部 特异于fas配体的单克隆抗体及其用途
CN115894675B (zh) * 2023-02-03 2023-11-14 康复大学(筹) 新冠病毒SARS-CoV-2核衣壳蛋白单克隆抗体及其应用
KR20260017010A (ko) * 2023-04-24 2026-02-04 엘피스 바이오파마슈티컬즈 장갑 항-b7h3 car-t 세포 및 암 치료에 있어서의 그 용도
WO2025096542A2 (en) * 2023-10-30 2025-05-08 Immunitas Therapeutics, Inc. Clec2d binding proteins and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US7147854B2 (en) 1997-06-23 2006-12-12 Yes Biotech Laboratories Ltd. Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
US20040001804A1 (en) * 1999-12-30 2004-01-01 Mathew Porunelloor A. LLT uses thereof in immune system modulation
EP3443981B1 (en) * 2010-06-29 2021-03-10 Centre National de la Recherche Scientifique (CNRS) Llt-1 antibodies with new functional properties
US9111624B2 (en) 2013-03-22 2015-08-18 Katsuyuki Fujita Semiconductor memory device
KR20220007584A (ko) * 2019-02-11 2022-01-18 주무토르 바이오로직스 인코포레이티드 항-clec2d 항체 및 이의 사용 방법

Also Published As

Publication number Publication date
JP7612591B2 (ja) 2025-01-14
CA3129818A1 (en) 2020-08-20
US12460007B2 (en) 2025-11-04
JP2025062598A (ja) 2025-04-14
US20240010733A1 (en) 2024-01-11
KR20220007584A (ko) 2022-01-18
WO2020167668A1 (en) 2020-08-20
JP2022521705A (ja) 2022-04-12
US20200291120A1 (en) 2020-09-17
US11827710B2 (en) 2023-11-28
AU2020222891A1 (en) 2021-08-05
EP3924385A1 (en) 2021-12-22
SG11202108403UA (en) 2021-08-30
IL285401A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
NZ778293A (en) Anti-clec2d antibodies and methods of use thereof
PH12020551907A1 (en) Antagonizing cd73 antibody
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
PH12020551317A1 (en) Anti-cd73 antibodies and methods of use thereof
NZ754051A (en) Novel antibodies and uses thereof
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2021127200A8 (en) Ilt3-binding agents and methods of use thereof
ZA202201874B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
MY194669A (en) Binding Proteins and Methods of use Thereof
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
WO2016187220A3 (en) Anti-ror1 antibodies
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
UA112416C2 (uk) Антитіло до fap і способи його застосування
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
DOP2016000282A (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
WO2020076969A3 (en) Anti-lap antibody variants and uses thereof
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
EP4477270A3 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
MX2023011712A (es) Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
MX2021005085A (es) Formulacion de anticuerpo.
MX2020007628A (es) Composiciones y metodos de uso.